Shanghai Model Organisms Center, Inc. (SHA:688265)
53.42
+1.42 (2.73%)
Sep 23, 2026, 3:00 PM CST
SHA:688265 Revenue
Shanghai Model Organisms Center had revenue of 132.52M CNY in the quarter ending June 30, 2026, with 23.43% growth. This brings the company's revenue in the last twelve months to 457.70M, up 14.38% year-over-year. In the year 2025, Shanghai Model Organisms Center had annual revenue of 421.02M with 10.44% growth.
Revenue (ttm)
457.70M
Revenue Growth
+14.38%
P/S Ratio
9.02
Revenue / Employee
477.27K
Employees
848
Market Cap
4.13B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 421.02M | 39.78M | 10.44% |
| Dec 31, 2024 | 381.24M | 14.69M | 4.01% |
| Dec 31, 2023 | 366.55M | 63.58M | 20.99% |
| Dec 31, 2022 | 302.97M | 27.70M | 10.06% |
| Dec 31, 2021 | 275.27M | 79.08M | 40.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hefei Lifeon Pharmaceutical | 1.51B |
| Kexing Biopharm | 1.44B |
| Pulike Biological Engineering | 1.02B |
| Beijing Bohui Innovation Biotechnology Group | 816.14M |
| Landfar Bio-medicine | 660.26M |
| Lifecome Biochemistry | 470.43M |
| Assure Tech (Hangzhou) | 410.36M |
| Beijing Scitop Bio-tech | 372.08M |